Table 2 Percentage change in COPD and asthma prescriptions rates from 2004 to 2020 with 95% CI
COPD and asthma medications | Prescriptions rate in 2004 prescriptions per 100,000 persons (95% CI) | Prescriptions rate in 2020 prescriptions per 100,000 persons (95% CI) | % change from 2004 to 2020 (%) | 95% confidence interval |
|---|---|---|---|---|
Bronchodilators | Â | Â | Â | Â |
Total | 50,132.91 (50,119.50–50,146.31) | 56,217.53 (56,204.95–56,230.12) | 12.1 | 11.31–12.96 |
Adrenoceptor agonists | Â | Â | Â | Â |
 Total | 40,059.54 (40,046.40–40,072.68) | 42,624.80 (42,612.25–42,637.34) | 6.4 | 5.78–7.02 |
 Selective β2 agonists | 39,729.43 (39,716.31–39,742.55) | 42,619.21 (42,606.67–42,631.75) | 7.3 | 6.64–7.96 |
 Other adrenoceptor agonists | 330.11 (328.57–331.65) | 5.59 (5.40–5.78) | − 98.3 | − 97.97 to − 98.63 |
Antimuscarinic bronchodilators | 4884.60 (4878.82–4890.38) | 9733.11 (9725.60–9740.63) | 99.3 | 99.09–99.51 |
Theophylline | 2098.36 (2094.51–2102.20) | 1322.37 (1319.47–1325.26) | − 37.0 | − 35.78 to − 38.22 |
Compound bronchodilator preparations | 3090.41 (3085.77–3095.05) | 2537.26 (2533.27–2541.24) | − 17.9 | 16.93–18.87 |
Inhaled corticosteroids | 27,246.10 (27,234.16–27,258.04) | 38,216.42 (38,204.09–38,228.74) | 40.3 | 39.06–41.54 |
Cromoglycate, leukotriene and phosphodiesterase type-4 Inhibitors | Â | Â | Â | Â |
Total | 1366.51 (1363.39–1369.62) | 5733.39 (5727.49–5739.29) | 319.6 | 318.42–320.78 |
Cromoglycate and related therapy | 147.11 (146.08–148.14) | 16.93 (16.60–17.26) | − 88.5 | 87.69–89.31 |
Leukotriene receptor antagonists | 1219.40 (1216.45–1222.34) | 5707.33 (5701.45–5713.21) | 368.0 | 366.78–369.22 |
Phosphodiesterase type-4 inhibitors | < 0.01 (0.00–0.01) *In 2011 | 9.13 (8.89–9.37) | 516,325.1 *from 2011 | 516,323.73–516,326.27 |